TAG:
quality control
New Market Channel For Esoteric Testing
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Employers Ready To Push Hospitals, Docs On Quality
By Robert Michel | From the Volume IX No. 9 – June 24, 2002 Issue
FOR THE SECOND TIME THIS YEAR, an influential group of large employers has publicly declared its intent to push hospitals and physicians to do more to improve the cost and quality of healthcare. On June 10, the Midwest Business Group declared that it was time for companies to “cra…
Pathology Part A Comp Under Attack by Both Hospitals and Insurers
By Robert Michel | From the Volume IX No. 4 – March 11, 2002 Issue
CEO SUMMARY: In steadily-growing numbers, hospitals and insurers are taking active steps to reduce or eliminate compensation for clinical pathology professional services, also commonly referred to as “Part A” services. Unfortunately, many pathology groups fail to anticipate this situati…
“Lean” Management Helps Bay Care’s Lab Boost Quality
By Robert Michel | From the Volume VIII No. 14 – October 15, 2001 Issue
CEO SUMMARY: All laboratory managers and pathologists face the same challenge: do more testing with less money. This challenge is further complicated by the fact that there are inadequate numbers of trained laboratory professionals available to staff the nation’s laboratories. Now, earl…
New Cytology Technology Entering Study Phase
By Robert Michel | From the Volume VIII No. 5 – April 9, 2001 Issue
CEO SUMMARY: There’s a new contestant in the ongoing battle to win the Pap smear technology wars. Ampersand Medical Corporation, by signing a strategic alliance with AmeriPath, Inc., has signaled that it’s ready to bring its technology to market. AmeriPath will play a major role in ex…
Tissue Banking May Be Source Of New Pathology Revenues
By Robert Michel | From the Volume VIII No. 5 – April 9, 2001 Issue
CEO SUMMARY: Evidence is accumulating that tissue banking may be where the “rubber meets the road;” where pharma money funds technology enhancements that directly benefit the profession of pathology. Without question, the need by pharma, biotech, and genomic companies to access, analy…
Accurate Costing of New Pap Technology Proves Interesting
By Robert Michel | From the Volume VII No. 13 – September 11, 2000 Issue
CEO SUMMARY: Various new technologies intended to supplant conventional Pap smear screening must deliver improved clinical performance in a cost-effective manner. Joseph Plandowski, our guest writer,concludes his three-part series on new Pap smear technologies by evaluating actual lab cos…
Market Hesitates to Embrace Automated Screening Products
By Robert Michel | From the Volume VII No. 12 – August 21, 2000 Issue
CEO SUMMARY: Technology to enhance and improve conventional Pap smear screening was introduced into the clinical marketplace almost five years ago. But the clinical laboratory industry has yet to embrace these various technologies in any meaningful way. Like the introduction of liquid pre…
Point-Of-Care Chemistry Ready To Transform Labs
By Robert Michel | From the Volume VI No. 16 – November 22, 1999 Issue
CEO SUMMARY: Following on the heels of our prediction about web-based test ordering/results reporting, here’s another equally revolutionary development. CARESIDE, Inc. is ready to launch a point-of-care instrument suite for routine, high-volume chemistry and hematology tests. Early peek…
California Assesses Fines After Needle Reuse by SBCL Employee
By Robert Michel | From the Volume VI No. 11 – August 9, 1999 Issue
ONE CHAPTER HAS CONCLUDED in the story about the phlebotomist who was discovered last March to be reusing butterfly needles in Palo Alto, California. California’s Department of Health Services (DHS) fined SmithKline Beecham Clinical Laboratories (SBCL) a total of…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized